

Drugs General Report

NAME	STATUS
Amitriptyline Metabolization	CYP2D6 Poor metabolizer/CYP2C19 Intermediate metabolizer
Aripiprazole Metabolization	Poor metabolizer
Brexpiprazole Metabolization	Poor metabolizer
Carbamazepine Metabolization	Ultrarapid metabolizer
Cardiovascular diseases and response to pravastatin	Probably does not respond adequately to pravastatin
Citalopram Metabolization	Intermediate metabolizer
Clomipramine Metabolization	CYP2D6 Poor metabolizer/CYP2C19 Intermediate metabolizer
Clozapine Metabolization	Poor metabolizer
Codeine Metabolization	Poor metabolizer
Cyclosporine Metabolization	Poor metabolizer
Desipramine Metabolization	Poor metabolizer
Diazepam Metabolization	Intermediate metabolizer
Disulfiram (Antabuse) and alcoholism	Sensitive to disulfiram
Escitalopram Metabolization	Intermediate metabolizer
Esomeprazole Metabolization	Intermediate metabolizer
Fluoropyrimidines Metabolization (Fluorouracil, Capecitabine, Tegafur)	Intermediate metabolizer
Fluoxetine Metabolization	Poor metabolizer
Fluvoxamine Metabolization	Poor metabolizer
Haloperidol Metabolization	Poor metabolizer
Iloperidone Metabolization	Poor Metabolizer
Lansoprazole Metabolization	Intermediate metabolizer

Drugs General Report

NAME	STATUS
Metabolization of Clopidogrel	Intermediate metabolizer
Metabolization of Prasugrel	Intermediate metabolizer
Metabolization of Ticagrelor	Intermediate metabolizer
Methotrexate and side effects in rheumatoid arthritis	Slightly increased risk of adverse effects
Methotrexate response in arthritis	Inefficient response
Metoprolol Metabolization	Poor metabolizer
Nortriptyline Metabolization	Poor metabolizer
Omeprazole Metabolization	Intermediate metabolizer
Pantoprazole Metabolization	Intermediate metabolizer
Paroxetin Metabolization	Poor metabolizer
Perphenazine Metabolization	Poor metabolizer
Pimozide Metabolization	Poor metabolizer
Propranolol Metabolization	Poor metabolizer
Rabeprazole Metabolization	Intermediate metabolizer
Response to Cyclophosphamide (and other chemotherapeutic agents) in breast cancer	Highly diminished response
Response to Valproic Acid and adverse effects	May suffer adverse effects associated with VPA
Risperidone Metabolization	Poor metabolizer
Selection of Prasugrel, Ticagrelor and Clopidogrel in Cardiovascular Diseases	Intermediate metabolizer
Sertraline Metabolization	Intermediate metabolizer
Statins and myopathy	Increased risk
Tramadol Metabolization	Poor metabolizer

Drugs General Report

NAME	STATUS
Venlafaxine Metabolization	Poor metabolizer
Voriconazole Metabolization	Intermediate metabolizer
Warfarin Metabolization	Intermediate metabolizer
Zuclopenthixol Metabolization	Poor metabolizer
Abacavir hypersensitivity	Normal
Acenocoumarol and Phenprocoumon Metabolization	Normal or extensive metabolizer
Acetaldehyde toxicity	Normal
Celecoxib Metabolization	Normal or extensive metabolizer
Fluorouracil toxicity	Normal
Glipizide Metabolization	Normal or extensive metabolizer
Hepatitis C response to treatment	Read Technical Report
Irinotecan and colorectal cancer	Read Technical Report
Ivacaftor and Cystic Fibrosis	Does not present the disease
Mercaptopurine Metabolization	Normal or extensive metabolizer
Mipomersen and familial hypercholesterolemia	No symptoms
Phenytoin Metabolization	Normal or extensive metabolizer
Phenytoin sensitivity	Normal
Pseudocholinesterase deficiency	Normal Risk
Sulfonylurea metabolism	Normal
Tacrolimus Metabolization in Transplants	Poor metabolizer
Thiopurine methyltransferase enzyme activity	Normal

Drugs General Report

NAME	STATUS
Antidepressants and Blood-Brain Barrier	Input level of antidepressants to the brain slightly increased (improved response)
Antidiabetics Response (sulphonylureas)	Usual response
Aspirin and asthma	Normal
Aspirin and cardiovascular risk	Normal
Aspirin and colorectal cancer	Normal
Asthma and inhaled corticosteroids	Read Technical Report
Cabozantinib response and medullary thyroid cancer	Does not respond to treatment
Caffeine metabolism	Poor metabolizer
Cisplatin response	Read Technical Report
Donepezil Metabolization (applicable to Galantamine)	No data
Fentanyl Metabolization	Poor metabolizer
Gemcitabine Response in pancreatic cancer	Diminished response
Glimepiride, Glyburide and Glicazide Metabolization	Normal or extensive metabolizer
High blood pressure treatment with common drugs	It is better to treat with calcium channel blockers drugs
Metformin response	Usual response
Paclitaxel (chemotherapy) and development of neuropathies	Increased neuropathy risk
Paclitaxel Metabolization (chemotherapy) and toxicity	Normal or extensive metabolizer (usual toxicity)
Palonosetron Metabolization	Poor metabolizer
Post-operative nausea and vomiting	Normal
Response to Chlorthalidone	Usual response
Response to olaparib in breast and ovarian cancer	Does not respond to olaparib

Drugs General Report

NAME	STATUS
Response to -blockers (Metoprolol, Carvedilol, Propranolol)	Increased response
Risperidone Response	Responds better than usual to risperidone
Tamoxifen Metabolization in Breast Cancer (Prognosis)	Poor metabolizer
Tolbutamide Metabolization	Normal or extensive metabolizer
Ziprasidone Response	Normal response to ziprasidone
Acenocoumarol and Phenprocoumon Response	Higher sensitivity than normal
Atenolol Response	Increased response
Bevacizumab response in Colorectal Cancer	Increased response
Bleomycin and Testicular (germ cell) Cancer	Normal
Bupropion (Zyban)	Normal
Carbamazepine and side effects	Likely to have an adverse reaction
Carisoprodol Metabolization	Intermediate metabolizer
Clobazam Metabolization	Intermediate metabolizer
Cyclophosphamide Toxicity (and other chemotherapeutic agents)	High risk of severe side effects
Duloxetine Response	High response to duloxetine
Floxacin toxicity	Normal
Fluoxetine, Citalopram and Escitalopram Response	Better response than usual
Gefitinib and lung cancer	Increased diarrhea risk
Gemcitabine and pancreatic cancer	Normal response
lloperidone and prolongation of the QTc interval	Probable risk of QT interval prolongation
LUM/IVA and Cystic Fibrosis	It does not present the deletion. Treatment not recommended

Drugs General Report

NAME	STATUS
Methotrexate and response to transplants	Common risk of rejection
Methotrexate and side effects in cancer treatment	Slightly increased risk of adverse effects
Mirtazapine Response	High response to mirtazapine
Naltrexone and alcoholism	Increased response to Naltrexone
Nelfinavir Metabolization (HIV)	Intermediate metabolizer
Olanzapine and weight gain	Much more likely
Opioids Response (Morphine, Oxycodone and Fentanyl)	Inefficient response
Paclitaxel Response (chemotherapy)	Usual response
Response to Furosemide and Torasemide	Decreased response
Response to Hydrochlorothiazide	Better response
Response to Lithium in Bipolar Disorder	Effective response
Response to imatinib	Respond to treatment
Risperidone and weight gain	Much more likely
Rosiglitazone response in diabetics	Increased response to Rosiglitazone
Sildenafil effect (Viagra®)	Increased response to Sildenafil
Simvastatin Metabolization	Normal or extensive metabolizer
Venlafaxine Response	Elevated response to venlafaxine
Vincristine Response	Normal relapse risk
Warfarin Response	Higher sensitivity than normal
Alfentanil Response	Inefficient response
Antipsychotics and weight gain (amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, quetiapine, risperidone, ziprasidone, paliperidone)	Usual risk of weight-gain

Drugs General Report

NAME	STATUS
Aspirin resistance and prothrombotic effect	Aspirin resistance
Bisoprolol Response	High response
Bupropion and Side Effects	Significantly decreased side effects
COPD treatment (Combined corticosteroid + B2 agonist treatment)	Better response
Carvedilol Metabolization	Poor metabolizer
Docetaxel and Leukopenia/neutropenia	Less risk
Gemcitabine Response in breast cancer	Inefficient response
Gemcitabine Response in mesothelioma	Efficient response
Gemcitabine Response in non-small cell lung cancer	Inefficient response
Gemcitabine Toxicity in pancreatic cancer	Increased risk of toxicity
Hypersensitivity to Vaccination	Some possibility of adverse reaction
lloperidone response	Efficient response
Methadone. Heroin addiction	Normal
Montelukast metabolization	Normal or extensive metabolizer
Montelukast response	Efficient response
Morphine and adverse effects	Usual risk of side effects
Nelfinavir Response (HIV)	Increased response
Olanzapine and schizophrenia	Normal
Quetiapine Metabolization	Normal or extensive metabolizer
Response to Acetylcholinesterase Inhibitors (ChEIs) in Alzheimer's disease (galantamine, donepezil, rivastigmine)	Decreased response
Sexual dysfunction in response to SSRIs	Normal

Drugs General Report

<div><div></div><div></div><div></div><div></div><div></div><div></div></div>					
NAME					STATUS
Sildenafil (Viagra) Response					Increased response
Vincristine Metabolization					Poor metabolizer
Vincristine and adverse effects					Protective effect against side effects
Voriconazole and cell transporters					Decreased plasma levels